Logo image of YTEN

YIELD10 BIOSCIENCE INC (YTEN) Stock Fundamental Analysis

NASDAQ:YTEN - Nasdaq - US98585K8541 - Common Stock - Currency: USD

2.88  -2.38 (-45.25%)

After market: 2.89 +0.01 (+0.35%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to YTEN. YTEN was compared to 558 industry peers in the Biotechnology industry. YTEN has a bad profitability rating. Also its financial health evaluation is rather negative. YTEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

YTEN had negative earnings in the past year.
In the past year YTEN has reported a negative cash flow from operations.
In the past 5 years YTEN always reported negative net income.
YTEN had a negative operating cash flow in each of the past 5 years.
YTEN Yearly Net Income VS EBIT VS OCF VS FCFYTEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

YTEN's Return On Assets of -370.00% is on the low side compared to the rest of the industry. YTEN is outperformed by 96.74% of its industry peers.
Industry RankSector Rank
ROA -370%
ROE N/A
ROIC N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YTEN Yearly ROA, ROE, ROICYTEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for YTEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YTEN Yearly Profit, Operating, Gross MarginsYTEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

YTEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, YTEN has less shares outstanding
The number of shares outstanding for YTEN has been increased compared to 5 years ago.
The debt/assets ratio for YTEN is higher compared to a year ago.
YTEN Yearly Shares OutstandingYTEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
YTEN Yearly Total Debt VS Total AssetsYTEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -157.47, we must say that YTEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -157.47, YTEN is not doing good in the industry: 98.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -157.47
ROIC/WACCN/A
WACC9.13%
YTEN Yearly LT Debt VS Equity VS FCFYTEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

YTEN has a Current Ratio of 0.29. This is a bad value and indicates that YTEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.29, YTEN is doing worse than 96.57% of the companies in the same industry.
YTEN has a Quick Ratio of 0.29. This is a bad value and indicates that YTEN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of YTEN (0.29) is worse than 96.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
YTEN Yearly Current Assets VS Current LiabilitesYTEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for YTEN have decreased strongly by -1075.36% in the last year.
Looking at the last year, YTEN shows a very negative growth in Revenue. The Revenue has decreased by -86.67% in the last year.
Measured over the past years, YTEN shows a very negative growth in Revenue. The Revenue has been decreasing by -36.03% on average per year.
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, YTEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.95% on average per year.
Based on estimates for the next years, YTEN will show a very strong growth in Revenue. The Revenue will grow by 288.42% on average per year.
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
YTEN Yearly Revenue VS EstimatesYTEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
YTEN Yearly EPS VS EstimatesYTEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YTEN. In the last year negative earnings were reported.
Also next year YTEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YTEN Price Earnings VS Forward Price EarningsYTEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YTEN Per share dataYTEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as YTEN's earnings are expected to grow with 25.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.9%

More info and screens

0

5. Dividend

5.1 Amount

YTEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

YIELD10 BIOSCIENCE INC

NASDAQ:YTEN (5/15/2024, 8:18:42 PM)

After market: 2.89 +0.01 (+0.35%)

2.88

-2.38 (-45.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2024-05-08/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners1.81%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change0%
Market Cap44.35M
Analysts45.71
Price Target12.24 (325%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.51%
Min EPS beat(2)-2.19%
Max EPS beat(2)13.21%
EPS beat(4)1
Avg EPS beat(4)-5.53%
Min EPS beat(4)-17.65%
Max EPS beat(4)13.21%
EPS beat(8)2
Avg EPS beat(8)-4.93%
EPS beat(12)4
Avg EPS beat(12)-2.47%
EPS beat(16)6
Avg EPS beat(16)-1.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2300%
PT rev (3m)433.33%
EPS NQ rev (1m)-2300%
EPS NQ rev (3m)-738.09%
EPS NY rev (1m)0%
EPS NY rev (3m)19.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)101.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 739.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-32.44
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -370%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.86%
Cap/Sales 76.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -157.47
F-Score2
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)53.31%
Cap/Depr(5y)46.87%
Cap/Sales(3y)47.05%
Cap/Sales(5y)31.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%
EBIT growth 1Y-7.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.31%
EBIT Next 3Y16.98%
EBIT Next 5Y24.41%
FCF growth 1Y12.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.68%
OCF growth 3YN/A
OCF growth 5YN/A